Share This Article:

Myelin-associated serological targets as applicable to diagnostic tools to be used at the preclinical and transient stages of multiple sclerosis progression

Abstract Full-Text HTML Download Download as PDF (Size:652KB) PP. 80-86
DOI: 10.4236/oji.2011.13010    3,633 Downloads   7,493 Views   Citations

ABSTRACT

MS is a severe progressive autoimmune disease with slight short-term relapses in its course. Autoagression against vulnerable myelin-associated Ags results in multiple lesions throughout the CNS. Abnormal responses against nervous issues are mainly affected by cell-mediated and humoral immunity. The first one plays a key role in the restructuring of myelin, while the last one is a biomarker of MS and does not participate in the gradation of the disease. Wide-scale autoimmune attack towards nervous tissues leads to a stepwise demyelination with concomitant release of myelin Ags (epitope spreading), formation of Abs and, consequently, systematization of pro-inflammatory responses. Monitoring of antimyelin-antibodies (Abs: OSP, MOBP, BMP, MOG, PLP) in peripheral blood and cerebrospinal fluid (CSF) is just a brick for making the preclinical diagnosis of MS and timely implementation of predictive measures and preventive treatment. Major autoAbs and their target antigens are discussed in this chapter with a special emphasize on the possibility of their impact for identification of pre-morbid stages and differential diagnosis of MS.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Kostyushev, D. , Tsarev, I. , Gnatenko, D. , Paltsev, M. and Suchkov, S. (2011) Myelin-associated serological targets as applicable to diagnostic tools to be used at the preclinical and transient stages of multiple sclerosis progression. Open Journal of Immunology, 1, 80-86. doi: 10.4236/oji.2011.13010.

References

[1] Berger, T., Rubner, P., Schautzer, F., Egg, R., Ulmer, H., Mayringer, I., Dilitz, E., Deisenhammer, F. and Reindl, M. (2003) Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. New England Journal of Medicine, 349, 139-145. doi:10.1056/NEJMoa022328
[2] Lim, E.T., Berger, T., Reindl, M., Dalton, C.M., Fernando, K., Keir, G., Thompson, E.J., Miller, D.H. and Giovannoni, G. (2005) Anti-myelin antibodies do not allow earlier diagnosis of multiple sclerosis. Multiple Sclerosis Journal, 11, 492-494. doi:10.1191/1352458505ms1187sr
[3] Kuhle, J., Pohl, C., Mehling, M., Edan, G., Freedman, M.S., Hartung, H.P., Polman, C.H., Miller, D.H., Montalban, X., Barkhof, F., Bauer, L., Dahms, S., Lindberg, R., Kappos, L. and Sandbrink, R. (2007)Lack of association between antimyelin antibodies and progression to multiple sclerosis. New England Journal of Medicine, 356, 371-378. doi:10.1056/NEJMoa063602
[4] Belogurov, A.A. Jr., Kurkova, I.N., Friboulet, A., Thomas, D., Misikov, V.K., Zakharova, M.Y., Suchkov, S.V., Kotov, S.V., Alehin, A.I., Avalle, B., Souslova, E.A., Morse, H.C. 3rd, Gabibov, A.G. and Ponomarenko, N.A. (2008) Recognition and degradation of myelin basic protein peptides by serum autoantibodies: Novel biomarker for multiple sclerosis. Journal of Immunology, 180, 1258-1267.
[5] Hedegaard, C.J., Chen, N., Sellebjerg, F., S?rensen, P.S., Leslie, R.G., Bendtzen, K. and Nielsen, C.H. (2009) Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis: A role in regulating cytokine responses to MBP. Immunology, 128, 451-461. doi:10.1111/j.1365-2567.2008.02999.x
[6] Zaprianova, E., Majtényi, K., Deleva, D., Mikova, O., Filchev, A., Sultanov, B., Kolyovska, V., Sultanov, E., Christova, L., Kmetska, X. and Georgiev, D. (2004) Serum IgG and IgM ganglioside GM1 antibodies in patients with multiple sclerosis. Ideggyógyászati Szemle, 57, 94-99
[7] Acarín, N., Río, J., Fernández, A.L., Tintoré, M., Durán, I., Galán, I. and Montalban, X. (1996) Different antiganglioside antibody pattern between relapsing-remitting and progressive multiple sclerosis. Acta Neurologica Scandinavica, 93, 99-103.
[8] Gabibov, A.G., Ponomarcnko. N.A., Kozyr, A.V. et al. (2002) Catalytic antibodies and pathology: Human and mice models. Journal of Immunological Methods, 269, 197-211.
[9] Lalive, P.H., Menge, T., Delarasse, C., Della Gaspera, B., Pham-Dinh, D., Villoslada, P., von Büdingen, H.C. and Genain, C.P. (2006) Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 103, 2280-2285. doi:10.1073/pnas.0510672103
[10] Johns, T.G. and Bernard, C.C. (1999) The structure and function of myelin oligodendrocyte glycoprotein. Journal of Neurochemistry, 72, 1-9.
[11] von Budingen, H.C., Tanuma, N., Villoslada, P., Ouallet, J.C., Hauser, S.L. and Genain, C.P. (2001) Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination. Journal of Clinical Immunology, 21, 155-170. doi:10.1023/A:1011031014433
[12] McMahon, E.J., Bailey, S.L., Vanderlugt-Castaneda, C.L., Waldner, H. and Miller, S.D. (2005) Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nature Medicine, 11, 335-339. doi:10.1038/nm1202
[13] Delarasse, C., Daubas, P., Mars, L.T., Vizler, C., Litzenburger, T., Iglesias, A., Bauer, J., Della Gaspera, B., Schubart, A., Decker, L., et al. (2003) Myelin/oligodendrocyte glycoprotein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice. Journal of Clinical Investigation, 112, 544-553.
[14] Pagany, M., Jagodic, M., Bourquin, C., Olsson, T. and Linington, C. (2003) Genetic variation in myelin oligodendrocyte glycoprotein expression and susceptibility to experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 139, 1-8. doi:10.1016/S0165-5728(03)00124-3
[15] Derbinski, J., Schulte, A., Kyewski, B. and Klein, L. (2001) Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nature Immunology, 2, 1032-1039. doi:10.1038/ni723
[16] Pagany, M., Jagodic, M., Schubart, A., Pham-Dinh, D., Bachelin, C., van Evercooren, A.B., Lachapelle, F., Olsson, T. and Linington, C. (2003) Myelin oligodendrocyte glycoprotein is expressed in the peripheral nervous system of rodents and primates. Neuroscience Letters, 350, 165-168. doi:10.1016/S0304-3940(03)00899-1
[17] Schluesener, H.J., Sobel, R.A., Linington, C. and Weiner, H.L. (1987) A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. Journal of Immunology, 139, 4016-4021.
[18] Iglesias, A., Bauer, J., Litzenburger, T., Schubart, A. and Linington, C. (2001) T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia, 36, 220-234. doi:10.1002/glia.1111
[19] Karni, A., Bakimer-Kleiner, R., Abramsky, O. and Bennun, A. (1999) Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Archives of Neurology, 56, 311-315. doi:10.1001/archneur.56.3.311
[20] Lolli, F., Rovero, P., Chelli, M. and Papini, A.M. (2005) Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis. Neurology, 65, 781-782.
[21] Klawiter, E.C, Piccio, L., Lyons, J.-A, Mikesell, R., Kevin, C., O’Connor and Anne H. (2010) Intrathecal anti-mog antibody production is elevated in multiple sclerosis. Archives of Neurology, 67, 1102-1108. doi:10.1001/archneurol.2010.197
[22] Lalive, P.H., H?usler, M.G., Maurey, H., Mikaeloff, Y., Tardieu, M., Wiendl, H., Schroeter, M., Hartung, H.P., Kieseier, B.C. and Menge, T. (2011) Highly reactive antimyelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Multiple Sclerosis Journal, 17, 297-302. doi:10.1177/1352458510389220
[23] de Rosbo, N.K., Kaye, J.F., Eisenstein, M., Mendel, I., Hoeftberger, R., Lassmann, H., Milo, R. and Ben-Nun, A. (2004) The myelin-associated oligodendrocytic basic protein region MOBP15-36 encompasses the immunodominant major encephalitogenic epitope(s) for SJL/J mice and predicted epitope(s) for multiple sclerosis-associated HLA-DRB1*1501. Journal of Immunology, 173, 1426-1435.
[24] Kaye, J.F., Kerlero de Rosbo, N., Mendel, I., Flechter, S., Hoffman, M., Yust, I., Ben-Nun, A. (2000) The central nervous system-specific myelin oligodendrocytic basic protein (MOBP) is encephalitogenic and a potential target antigen in multiple sclerosis (MS). Journal of Neuroimmunology, 102, 189-198. doi:10.1016/S0165-5728(99)00168-X
[25] Babbe, H., Roers, A., Waisman, A., et al. (2000)Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. Journal of Experimental Medicine, 192, 393-404. doi:10.1084/jem.192.3.393
[26] Aslam, M., Kalluri, S.R., Cepok, S., Kraus, V., Buck, D., Srivastava, R., Hemmer, B.J. (2010) The antibody response to oligodendrocyte specific protein in multiple sclerosis. Journal of Neuroimmunology, 221, 81-86. doi:10.1016/j.jneuroim.2010.02.008
[27] Bronstein, J. M., Popper, P., Micevych, P.E. and Farber, D.B. (1996) Isolation and characterization of a novel oligodendrocyte-specific protein. Neurology, 47, 772.
[28] Chow, E., Mottahedeh, J., Prins, M., Ridder, W., Nusinowitz, S. and Bronstein, J.M. (2005) Disrupted compaction of CNS myelin in an OSP/Claudin-11 and PLP/ DM20 double knockout mouse. Molecular and Cellular Neuroscience, 29, 405-413. doi:10.1016/j.mcn.2005.03.007
[29] Zhong, M.C., Cohen, L., Meshorer, A., Kerlero de Rosbo, N., Ben-Nun, A. (2000) T-cells specific for soluble recombinant oligodendrocyte-specific protein induce severe clinical experimental autoimmune encephalomyelitis in H-2(b) and H-2(s) mice. Journal of Neuroimmunology, 105, 39-45. doi:10.1016/S0165-5728(00)00186-7
[30] Kaushansky, N., Zhong, M.C., Kerlero de Rosbo, N., Hoeftberger, R., Lassmann, H. and Ben-Nun, A. (2006) Epitope specificity of autoreactive T and B cells associated with experimental autoimmune encephalomyelitis and optic neuritis induced by oligodendrocyte-specific protein in SJL/J mice. Journal of Immunology, 177, 7364-7376.
[31] Stevens, D.B., Chen, K., Seitz, R.S., Sercarz, E.E. and Bronstein, J.M. (1999) Oligodendrocyte-specific protein peptides induce experimental autoimmune encephalomyelitis in SJL/J mice. Journal of Immunology, 162, 7501-7509.
[32] Sobel R.A. (1989) T-lymphocyte subsets in the multiple sclerosis lesion. Research in Immunology, 140, 208-211. doi:10.1016/0923-2494(89)90088-6
[33] Lee, S.J., Wucherpfennig, K.W., Brod, S.A., Benjamin, D., Weiner, H.L. and Hafler, D.A. (1991) Common T cell receptor V beta usage in oligoclonal T lymphocytes derived from cerebrospinal fluid and blood of patients with multiple sclerosis. Annals of Neurology, 29, 33-40. doi:10.1002/ana.410290109
[34] Aslam, M., Kalluri, S.R., Cepok, S., Kraus, V., Buck, D., Srivastava, R. and Hemmer, B. (2010) The antibody response to oligodendrocyte specific protein in multiple sclerosis. Journal of Neuroimmunology, 221, 81-86. doi:10.1016/j.jneuroim.2010.02.008
[35] Greer, J. M., Sobel, R.A., Sette, A., Southwood, S.,Lees, M.B. and Kuchroo, V.K. (1996.) Immunogenic and encephalitogenic epitope clusters of myelin proteolipid protein. Journal of Immunology, 156, 371-379.
[36] Greer, J.M., Csurhes, P.A., Muller, D.M., Pender, M.P. (2008) Correlation of blood T cell and antibody reactivity to myelin proteins with HLA type and lesion localization in multiple sclerosis. Journal of Immunology, 180, 6402-6410.
[37] Pender, M.P., Csurhes, P.A., Greer, J.M., Mowat, P.D., Henderson, R.D., Cameron, K.D., Purdie, D.M., McCombe, P.A. and Good, M.F. (2000) Surges of increased T cell reactivity to an encephalitogenic region of myelin proteolipid protein occur more often in patients with multiple sclerosis than in healthy subjects. Journal of Immunology, 165, 5322-5331.
[38] Tuohy, V.K., Yu, M., Weinstock-Guttman, B. and Kinkel, P.R. (1997) Diversity and plasticity of self recognition during the development of multiple sclerosis. Journal of Clinical Investigation, 99, 1682-1690. doi:10.1172/JCI119331
[39] H?ftberger, R., Fink, S., Aboul-Enein, F., Botond, G., Olah, J., Berki, T., Ovadi, J., Lassmann, H., Budka, H., Kovacs, G.G. (2010)Tubulin polymerization promoting protein (TPPP/p25) as a marker for oligodendroglial changes in multiple sclerosis. Glia, 58, 1847-1857. doi:10.1002/glia.21054
[40] Vincze, O., Oláh, J., Zádori, D., Klivényi, P., Vécsei, L. and Ovádi, J. (2011) A new myelin protein, TPPP/p25, reduced in demyelinated lesions is enriched in cerebrospinal fluid of multiple sclerosis. Biochemical and Biophysical Research Communications, 409, 137-141. doi:10.1016/j.bbrc.2011.04.130

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.